• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Cystic Fibrosis - Articles and news items

Laurent Pharmaceuticals receive $3 million for Cystic Fibrosis clinical trial

Industry news / 27 July 2016 / Niamh Louise Marriott, Digital Content Producer

Laurent Pharmaceuticals has received a Therapeutics Development Award of $3 million from US-based Cystic Fibrosis Foundation Therapeutics…

Exploring the need for mutation-specific treatments in cystic fibrosis

Blog, Z Homepage promo / 1 July 2016 / Caroline Richards, Editor, European Pharmaceutical Review

Here, Caroline Richards, Editor of European Pharmaceutical Review, discusses cystic fibrosis and the treatment options that are currently available or in development…

Verona secures funding commitments to help progress RPL554

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Verona Pharma has successfully secured funding commitments to raise gross proceeds of £44.7m through a conditional placing with new and existing investors…

Orkambi’s cost too high for benefit offered, says NICE

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

NICE has said it will not be able to recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis…

Polyphor successfully completes Phase I study with POL6014

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

POL6014 is a highly selective, potent and reversible inhibitor of hNE. Increased levels of hNE is associated with cystic fibrosis…

SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

While the SMC has rejected Kalydeco and Orkambi, The Cystic Fibrosis Trust has put forward a solution for the drugs to be considered by the NMF…

Polyphor awarded $3 million to advance POL6014 in CF

Industry news / 23 March 2016 / Victoria White

Polyphor’s POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess…

NICE says ‘no’ to cystic fibrosis drug Orkambi in draft guidance

Industry news / 23 March 2016 / Victoria White

The independent appraisal committee concluded that the cost of Orkambi was considerably higher than the current standard of care and is not cost effective…

European Pharmaceutical Review’s top 10 stories from 2015

Blog / 28 January 2016 / Victoria White, Digital Content Producer, European Pharmaceutical Review

2015 was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines…

EC grants marketing authorisation for cystic fibrosis drug Orkambi

Industry news / 20 November 2015 / Victoria White

Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis…

PTC submits EU application for Translarna for cystic fibrosis

Industry news / 30 September 2015 / Victoria White

If approved, Translarna would be the first oral protein restoration treatment that targets the underlying cause of nonsense mutation cystic fibrosis…

New data will be presented for Roche’s Esbriet in idiopathic pulmonary fibrosis at European Respiratory Society Congress 2015

Supplier news / 21 September 2015 / Roche

Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015…

  • Page 1 of 2
  • 1
  • 2
  • >